Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Not Confirmed
Not Confirmed
28-30 September, 2024
Discovery on TargetDiscovery on Target
Not Confirmed
Not Confirmed
30 September-03 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Industry Trade Show
Not Confirmed
28-30 September, 2024
Discovery on TargetDiscovery on Target
Industry Trade Show
Not Confirmed
30 September-03 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
09 Sep 2024
// BUSINESSWIRE
https://www.fiercepharma.com/pharma/cash-crunched-immunitybio-heels-fda-nod-lays-staffers-california-colorado
05 Sep 2024
// FIERCE PHARMA
https://www.fiercepharma.com/pharma/cash-crunched-immunitybio-heels-fda-nod-lays-staffers-california-colorado
04 Sep 2024
// BIOSPACE
https://www.biospace.com/job-trends/immunitybio-to-lay-off-16-will-likely-need-additional-capital
12 Aug 2024
// BUSINESSWIRE
06 Aug 2024
// BUSINESSWIRE
Details:
Anktiva (nogapendekin alfa inbakicept-pmln) is a IL-15 receptor agonist, which is being evaluated in combination with AdHER2DC vaccine for the treatment of endometrial cancer.
Lead Product(s): Nogapendekin Alfa Inbakicept,AdHER2DC,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Phase I/ Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 06, 2024
Lead Product(s) : Nogapendekin Alfa Inbakicept,AdHER2DC,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ImmunityBio Announces Study of ANKTIVA in Combination with AdHER2DC as a Potential Therapy
Details : Anktiva (nogapendekin alfa inbakicept-pmln) is a IL-15 receptor agonist, which is being evaluated in combination with AdHER2DC vaccine for the treatment of endometrial cancer.
Brand Name : Anktiva
Molecule Type : Large molecule
Upfront Cash : Not Applicable
August 06, 2024
Details:
With the termination, LadRx regains control of INNO-206 (aldoxorubicin), a rationally-engineered cytotoxic which delivers well-established anti-cancer agent, doxorubicin, into the tumor.
Lead Product(s): Aldoxorubicin
Therapeutic Area: Oncology Brand Name: INNO-206
Study Phase: Phase IIIProduct Type: Small molecule
Recipient: LadRx
Deal Size: $356.0 million Upfront Cash: Undisclosed
Deal Type: Termination June 03, 2024
Lead Product(s) : Aldoxorubicin
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : LadRx
Deal Size : $356.0 million
Deal Type : Termination
LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License
Details : With the termination, LadRx regains control of INNO-206 (aldoxorubicin), a rationally-engineered cytotoxic which delivers well-established anti-cancer agent, doxorubicin, into the tumor.
Brand Name : INNO-206
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 03, 2024
Details:
Through the agreement, the companies will concentrate on scaling up the manufacture of BCG for use in combination with Anktiva (Nogapendekin Alfa Inbakicept) to treat non-muscle invasive bladder cancer.
Lead Product(s): Nogapendekin Alfa Inbakicept,Recombinant Bacillus Calmette-Guerin
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Serum Institute of India
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 02, 2024
Lead Product(s) : Nogapendekin Alfa Inbakicept,Recombinant Bacillus Calmette-Guerin
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Serum Institute of India
Deal Size : Undisclosed
Deal Type : Agreement
Details : Through the agreement, the companies will concentrate on scaling up the manufacture of BCG for use in combination with Anktiva (Nogapendekin Alfa Inbakicept) to treat non-muscle invasive bladder cancer.
Brand Name : Anktiva
Molecule Type : Large molecule
Upfront Cash : Undisclosed
May 02, 2024
Details:
Anktiva™ (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex and which is investigated for advanced non-small cell lung cancer.
Lead Product(s): Nogapendekin Alfa Inbakicept,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Phase IIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 25, 2024
Lead Product(s) : Nogapendekin Alfa Inbakicept,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Anktiva™ (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex and which is investigated for advanced non-small cell lung cancer.
Brand Name : Anktiva
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 25, 2024
Details:
Anktiva (nogapendekin alfa inbakicept-pmln) is a IL-15 receptor agonist, which is being evaluated in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): Nogapendekin Alfa Inbakicept,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: ApprovedProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2024
Lead Product(s) : Nogapendekin Alfa Inbakicept,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-class IL-15 Receptor Agonist for BCG-Unr...
Details : Anktiva (nogapendekin alfa inbakicept-pmln) is a IL-15 receptor agonist, which is being evaluated in combination with Bacillus Calmette-Guérin (BCG) for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer.
Brand Name : Anktiva
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 22, 2024
Details:
Tri-Ad5 vaccine combination (hAd5 CEA/MUC1/brachyury) together with its IL-15 superagonist and immune enhancer N-803 is being evaluated in people with Lynch syndrome.
Lead Product(s): Ad5 CEA/MUC1/Brachyury Vaccine Tri-Ad5,Nogapendekin Alfa
Therapeutic Area: Oncology Brand Name: Tri Ad5
Study Phase: Phase IIProduct Type: Vaccine
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details : Tri-Ad5 vaccine combination (hAd5 CEA/MUC1/brachyury) together with its IL-15 superagonist and immune enhancer N-803 is being evaluated in people with Lynch syndrome.
Brand Name : Tri Ad5
Molecule Type : Vaccine
Upfront Cash : Not Applicable
February 21, 2024
Details:
The proceeds will also be used to fund company's clinical trials expanding N-803 (Anktiva), an interleukin-15 superagonist fusion protein, being developed for indications into multiple solid tumors, including BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: Oberland Capital
Deal Size: $320.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 02, 2024
Lead Product(s) : N-803,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Oberland Capital
Deal Size : $320.0 million
Deal Type : Financing
Details : The proceeds will also be used to fund company's clinical trials expanding N-803 (Anktiva), an interleukin-15 superagonist fusion protein, being developed for indications into multiple solid tumors, including BCG-unresponsive non-muscle invasive bladder ...
Brand Name : Anktiva
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 02, 2024
Details:
Anktiva (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2023
Lead Product(s) : N-803,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
Details : Anktiva (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease...
Brand Name : Anktiva
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 26, 2023
Details:
Anktiva (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 23, 2023
Lead Product(s) : N-803,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Anktiva (N-803 ), a lead cytokine fusion protein, is a novel IL-15 superagonist complex plus Bacillus Calmette-Guérin (BCG) for the treatment of BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ (CIS) with or without Ta or T1 disease...
Brand Name : Anktiva
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 23, 2023
Details:
The financing will fund company's ongoing business operations and pre-commercialization efforts as it continues to drive toward a potential regulatory approval of Anktiva (N-803), a novel IL-15 superagonist, plus BCG for BCG-unresponsive non-muscle invasive bladder cancer.
Lead Product(s): N-803,BCG Vaccine
Therapeutic Area: Oncology Brand Name: Anktiva
Study Phase: Phase II/ Phase IIIProduct Type: Large molecule
Sponsor: Nant Capital
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing September 11, 2023
Lead Product(s) : N-803,BCG Vaccine
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Nant Capital
Deal Size : Undisclosed
Deal Type : Financing
Details : The financing will fund company's ongoing business operations and pre-commercialization efforts as it continues to drive toward a potential regulatory approval of Anktiva (N-803), a novel IL-15 superagonist, plus BCG for BCG-unresponsive non-muscle invas...
Brand Name : Anktiva
Molecule Type : Large molecule
Upfront Cash : Undisclosed
September 11, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?